(Q33311569)

25 July 2017

1 reference

title

Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management (English)

1 reference

25 July 2017

0 references

0 references

1 reference

Katherine W Phillips

1

1 reference

25 July 2017

Jack Ansell

series ordinal

2

1 reference

25 July 2017

publication date

1 January 2008

1 reference

Expert Review of Cardiovascular Therapy

25 July 2017

published in

1 reference

25 July 2017

volume

6

1 reference

25 July 2017

issue

1

1 reference

25 July 2017

page(s)

57-70

1 reference

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

National surveillance of emergency department visits for outpatient adverse drug events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Clinical practice. Care of patients receiving long-term anticoagulant therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

A randomized trial comparing 5-mg and 10-mg warfarin loading doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Comparison of a daily fixed 2.5-mg warfarin dose with a 5-mg, international normalized ratio adjusted, warfarin dose initially following heart valve replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Risk factors for intracranial hemorrhage in outpatients taking warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

A systematic review of outcome measures reported for the therapeutic effectiveness of oral anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Anaphylactoid reactions to vitamin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Optimal oral anticoagulant therapy in patients with mechanical heart valves.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Relationship between patients' warfarin knowledge and anticoagulation control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Patients' perspectives on taking warfarin: qualitative study in family practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Impact of adherence, knowledge, and quality of life on anticoagulation control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Determinants of compliance with anticoagulation: A case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.1.57

21 January 2018

Identifiers

DOI

10.1586/14779072.6.1.57

1 reference

25 July 2017

1 reference